Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR

被引：0
|
作者：
Carmen M. Labandeira
Maria G. Alonso Losada
Rosa Yáñez Baña
Maria I. Cimas Hernando
Iria Cabo López
Jose M. Paz González
Maria J. Gonzalez Palmás
Cristina Martínez Miró
Diego Santos García
机构：
[1] CHUVI,Department of Clinical Neurology
[2] Complejo Hospitalario Universitario de Vigo,undefined
[3] CHUO,undefined
[4] Complejo Hospitalario Universitario de Ourense,undefined
[5] Hospital de Povisa,undefined
[6] CHOP,undefined
[7] Complejo Hospitalario Universitario de Pontevedra,undefined
[8] CHUAC,undefined
[9] Complejo Hospitalario Universitario de A Coruña,undefined
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Safinamide; Non-motor symptoms; Parkinson’s disease; Depression; Mood;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：5398 / 5411
页数：13
相关论文
共 50 条
  • [21] An open-label extension study to determine the safety of pimavanserin in patients with Parkinson's disease and psychosis
    Mills, R.
    Johnson, A. D.
    Bahr, D.
    Williams, H.
    Revell, S.
    MOVEMENT DISORDERS, 2009, 24 : S268 - S269
  • [22] An Open-Label Extension Study To Determine the Safety of Pimavanserin in Patients with Parkinson's Disease and Psychosis
    Mills, Roger
    Johnson, Ann D.
    Williams, Hilde
    Bahr, Daun
    Revell, Stephen
    NEUROLOGY, 2009, 72 (11) : A319 - A319
  • [23] An open-label extension study of modafinil for the treatment of daytime sleepiness in patients with Parkinson's disease
    Adler, CH
    Caviness, JN
    Hentz, JG
    Lind, M
    Tiede, J
    SLEEP, 2002, 25 : A251 - A252
  • [24] An open-label extension study to determine the safety of pirnavanserin in patients with Parkinson's disease and psychosis
    Mills, R.
    Johnson, A.
    Bahr, D.
    Williams, H.
    Revell, S.
    MOVEMENT DISORDERS, 2008, 23 (01) : S221 - S221
  • [25] Laserlight cues for gait freezing in Parkinson's disease: An open-label study
    Donovan, S.
    Lim, C.
    Diaz, N.
    Browner, N.
    Rose, P.
    Sudarsky, L. R.
    Tarsy, D.
    Fahn, S.
    Simon, D. K.
    PARKINSONISM & RELATED DISORDERS, 2011, 17 (04) : 240 - 245
  • [26] Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study (vol 9, 9, 2020)
    Reichmann, Heinz
    Lees, Andrew
    Rocha, Jose-Francisco
    Magalhaes, Diogo
    Soares-da-Silva, Patricio
    TRANSLATIONAL NEURODEGENERATION, 2020, 9 (01)
  • [27] Effect of Repeated Intravenous Amantadine Infusions in Patients with Parkinson's Disease: An Open-Label Pilot Study
    Khlebtovsky, Alexander
    Steiner, Israel
    Treves, Therese
    Djaldetti, Ruth
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2019, : 586 - 590
  • [28] The effect of prucalopride on gastric emptying in Parkinson's disease patients, a pilot randomized, open-label study
    Pinyopornpanish, Kanokwan
    Kijdamrongtham, Phuripong
    Soontornpun, Atiwat
    Teeyasoontranon, Waralee
    Angkurawaranon, Chaisiri
    Thongsawat, Satawat
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 113 - 113
  • [29] A 6-month open-label study of the effectiveness and tolerability of galantamine in patients with Alzheimer's disease
    Patterson, CE
    Passmore, AP
    Crawford, VLS
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (02) : 144 - 148
  • [30] Atomoxetine for the Treatment of Executive Dysfunction in Parkinson's Disease: A Pilot Open-Label Study
    Marsh, Laura
    Biglan, Kevin
    Gerstenhaber, Melissa
    Williams, James R.
    MOVEMENT DISORDERS, 2009, 24 (02) : 277 - 282
12345